Please assess the completion status of the following clinical trial:

Trial Title: Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* (ASA 1\&2),~* aging 18 to 65 years~* having anxiety VAS score of more than 2~* posted for general anaesthesia with estimated duration of \< 3 hours.~Exclusion Criteria:~* patients taking analgesics, sedatives, antiepileptics or antidepressants,~* suffering from obesity (BMI ≥ 28) or neuropsychiatric disease,~* having allergy to the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Melatonin (Type: PLACEBO_COMPARATOR): Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
- melatonin and alprazolam premedication (Type: PLACEBO_COMPARATOR): Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
- alprazolam premedication (Type: PLACEBO_COMPARATOR): Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
- placebo premedication (Type: ACTIVE_COMPARATOR): Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).